Partner Content Partner Content Poor Glycaemic Control and Tooth Loss Study Poor Glycaemic Control and Tooth Loss Study
Partner Content Partner Content First results of the DiabetRisk study First results of the DiabetRisk study
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
